Sustained release composition useful in the treatment of e.g. benign prostatic hyperplasia comprises Tamsulosin core with a coating containing combination of polyvinyl acetate and polyvinyl pyrrolidone

摘要

A sustained release pharmaceutical composition (C1) comprises: (a) a core of Tamsulosin in the form of base and/or salt; (b) a coating containing a combination of polyvinyl acetate (PVAC) and polyvinyl pyrrolidone (PVP); and (c) optionally at least one excipient. An independent claim is also included for the manufacture of (C1), which involves applying the coating to Tamsulosin, optionally in combination with an excipient. ACTIVITY : Cytostatic. MECHANISM OF ACTION : alpha -Adrenoceptor blocker.